Science
Next-Gen CGT Pipeline Powered by the FAST CGT Platform
Regulatory T cell Therapies
Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppressants for autoimmune disease treatment and transplant rejection prevention.
Product Name Adaption Preclinical Phase1 Phase2 Phase3
TregCelTM Solid organ transplantation (kidney)
Engineered Treg Autoimmune diseases
Engineered MSC Therapies
Utilizing the FAST CGT platform enhance therapeutic efficacy, durability, and precision of MSC therapies for treating inflammatory and ischemic diseases.
Product Name Adaption Preclinical Phase1 Phase2 Phase3
ChondrochymalTM Knee osteoarthritis
Biochymal Critical limb ischemia
Close menu